Trial Profile
A retrospective study assessing safety and efficacy of Ipilimumab in an elderly patients with melanoma.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Aug 2016
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 04 Aug 2016 New trial record
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology